Additionally, CL treatment markedly reduced liver fibrosis and activated HSC numbers in the liver, as assessed by SR staining and a-SMA immunostaining (Figures 6C, E–G; Supplemental Figure S5). This evidence concerns the gene SMN1 and Hepatic fibrosis.